Other FGFR inhibitors under investigation in patients with CCA include the pan-FGFR inhibitors erdafitinib (NCT02699606), KIN-3248 (NCT05242822), and ICP-192 (NCT05678270, selectively inhibits FGFR 1, 2, 3, and 4 activities irreversibly by covalent binding), the multikinase inhibitor derazantinib (NCT03230318), the bivalent FGFR1–3 inhibitor tasurgratinib (E7090, which blocks FGF–FGFR interactions; NCT04238715), and the FGFR1–3 inhibitor HMPL-453 (NCT04353375). This evidence concerns the gene FGFR1 and cholangiocarcinoma.